Literature DB >> 1849125

Effects of tyrosine kinase inhibitor, erbstatin, on cell growth and growth-factor/receptor gene expression in human gastric carcinoma cells.

N Takekura1, W Yasui, E Kyo, K Yoshida, T Kameda, Y Kitadai, K Abe, K Umezawa, E Tahara.   

Abstract

The effect of tyrosine kinase inhibitor, erbstatin, on cell growth and mRNA expression of growth-factor/receptor system was examined in 6 human gastric-carcinoma cell lines. Erbstatin inhibited both EGF-induced and serum-stimulated cell growth of all 6 cell lines (TMK-1, MKN-1, -7, -28, -45, -74) in a dose-dependent manner. 3H-thymidine incorporation by TMK-1 cells was also suppressed by erbstatin. Erbstatin inhibited protein kinase activity of EGF receptor, p185ERBB2 and pp60c-src in TMK-1 cells. The expression of mRNA of EGF receptor gene and ERBB-2 by TMK-1 cells was not changed by erbstatin treatment, whereas that of c-src was slightly decreased. Interestingly, erbstatin decreased membrane-bound TGF-alpha precursor as measured by anti-TGF-alpha antibody-binding assay, although mRNA expression for TGF-alpha was not altered by erbstatin. Our findings suggest that erbstatin may act as a growth inhibitor for human gastric-carcinoma cells and may not only inhibit tyrosine kinase activities but also negatively modulate the post-transcriptional step of TGF-alpha expression.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1849125     DOI: 10.1002/ijc.2910470626

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  2 in total

1.  Reg IV enhances peritoneal metastasis in gastric carcinomas.

Authors:  H Kuniyasu; N Oue; T Sasahira; L Yi; Y Moriwaka; T Shimomoto; K Fujii; H Ohmori; W Yasui
Journal:  Cell Prolif       Date:  2009-02       Impact factor: 6.831

2.  Monitoring the cytoskeletal EGF response in live gastric carcinoma cells.

Authors:  Marco Felkl; Kazmar Tomas; Matej Smid; Julian Mattes; Reinhard Windoffer; Rudolf E Leube
Journal:  PLoS One       Date:  2012-09-27       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.